Table 6.
Summary of dosimetry data for salivary and lacrimal glands in [177Lu]Lu-PSMA treatment of metastatic castration-resistant prostate cancer
| First author (year) | Ligand | # pats | Method for activity quantification | Method for AD calculation | AD per unit of administered activity (Gy/GBq) (Mean ± SD) | Mass (g) (mean ± SD) [range] | No. of considered cycles | Ref. |
|---|---|---|---|---|---|---|---|---|
| Delker (2016) | PSMA-617 | 5 | Planar: 1 h, 24 h, 48 h, 72 h | Sphere S-values | Salivary: 1.4 ± 0.5 | 38 ± 5 [31–43] | 2 | [12] |
| Kabasakal (2015) | PSMA-617 | 7 | Planar: 4 h, 24 h, 48 h, 120 h |
Sphere S-values Mass from CT delineation |
Parotid: 1.17 ± 0.31 | - | 1 (Pre-therapeutic tracer adm.) | [18] |
| Kratochwil (2016) | PSMA-617 | 4 | Planar: 0.5 h, 3 h, 20 h, 44 h, 5−8 days |
Sphere S-values Mass from PET/CT delineation |
Parotid: 1.28 ± 0.40 Submandibular: 1.48 ± 0.37 |
- | 2 | [54] |
| Baum (2016) | PSMA I&T | 30 |
Planar: 5 time-points 0.5 h to 118 h SPECT/CT: between 45 h and 118 h |
Olinda v.1 | Parotid: 1.3 ± 2.3, max: 9.5 | - | 1 | [187] |
| Scarpa (2017) | PSMA-617 | 10 |
Hybrid (for abdomen): Planar: 0.5 h, 4 h, 24 h, 72 h, 96 h SPECT/CT: 24 h |
Sphere S-values Mass from PET/CT delineation |
Parotid: 0.56 ± 0.25, max: 1.040 Submandibular: 0.50 ± 0.15, max: 0.660 Lacrimal: 1.01 ± 0.69, max: 2.7 |
Volumes: Parotid: 24.98 mL, max: 34 mL Submandibular: 8.63 mL, max:10.35 mL |
1 | [206] |
| Hohberg (2016) | DKFZ-PSMA-617 | 9 | Planar: 0.5 h, 24 h, 48 h, 72 h, 168 h |
Olinda v.1 ( AFs for thyroid with mass adjustment ) For lacrimal: sphere S-values Fixed masses for salivary and lacrimal |
Salivary (parotid + submandibular): 0.72 ± 0.14, max: 0.898 Lacrimal: 2.82 ± 0.76, max: 4.04 |
Salivary: 85 Lacrimal: 1.4 |
1 | [67] |
| Fendler (2017) | PSMA-617 | 10 | SPECT/CT: 24 h, 48 h, 72 h | No details | Salivary: 1.0 ± 0.6 | - | 2 | [22] |
| Kabasakal (2017) | PSMA-617 | 6 |
Hybrid: Planar: 4 h, 24 h, 48 h, 120 h SPECT/CT: 24 h |
Sphere S-values Mass from CT delineation |
Parotid: 1.9 ± 1.19 | - | 1 | [21] |
| Okamoto (2017) | PSMA I&T | 18 | Planar: 30–120 min, 24 h, 48 h, 72 h, 6–8 days |
Sphere S-values Mass from PET/CT delineation |
Parotid: 0.55 ± 0.14, max: 0.84 Submandibular: 0.64 ± 0.40, max: 1.70 Lacrimal: 3.8 ±1.4, max: 7.03 |
For one gland: Parotid: 19.1 ± 5.7 [8.0–35.6] Submandibular: 8.2 ± 1.9 [4.2–14.3] Lacrimal: 0.45 ± 0.12 [0.25–0.78] |
From 1 to 4 | [23] |
| Yadav (2017) | DKFZ-PSMA-617 | 26 | Planar: 0.5 h, 3.5 h, 24 h, 48 h, 72 h, 96 h, 120 h, 144 h, 168 h |
Sphere S-values Mass from SPECT/CT delineation |
Parotid: 1.31 ± 0.22 Submandibular: 1.11 ± 0.39 Salivary glands (Parotid + Submandibular): 1.24 ± 0.27, max: 1.85 |
- | 1 | [188] |
| Violet (2019) | PSMA-617 | 30 | SPECT/CT: 1 h, 24 h, 96 h |
2 methods: Voxel-based, VDK Sphere S-values (mass from PET/CT delineation) |
Parotid: 0.58 ± 0.43, max: 1.87 Submandibular: 0.44 ± 0.36, max: 1.75 Lacrimal: 0.36 ± 0.18, max: 0.81 |
- | 1 | [74] |
AD, absorbed dose; VDK, voxel dose kernel